{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:05:53Z","timestamp":1791187553092,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:00:00Z","timestamp":1182211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co\u2010morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co\u2010prescribed, suggesting possible cross\u2010sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti\u2010parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. \u00a9 2007 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21611","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T13:17:36Z","timestamp":1182259056000},"page":"1757-1763","source":"Crossref","is-referenced-by-count":195,"title":["Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series"],"prefix":"10.1002","volume":"22","author":[{"given":"David A.","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,19]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20045"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.4.423"},{"issue":"9","key":"e_1_2_6_5_2","first-page":"S195","article-title":"Gambling in Parkinson's disease","volume":"19","author":"Tyne HL","year":"2004","journal-title":"Mov Disord."},{"key":"e_1_2_6_6_2","first-page":"62","article-title":"Chronic dopamimetic drug addiction and pathologic gambling in patients with Parkinson's disease\u2010 presentation of four cases","volume":"5","author":"Serrano\u2010Duenas M","year":"2002","journal-title":"German J Psychiatry"},{"issue":"15","key":"e_1_2_6_7_2","first-page":"S657","article-title":"Pathological gambling (PG) in Parkinson's disease (PD) during ergot and non\u2010ergot dopamine agonists treatment","volume":"21","author":"Antonini A","year":"2006","journal-title":"Mov Disorder"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000076478.45005.EC"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.969"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218206.20920.4d"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21110"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238401.76928.45"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7247.1468"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0504"},{"key":"e_1_2_6_15_2","volume-title":"Gambling in Ontario: a report from a general population survey on gambling\u2010related problems and opinions","author":"Ferris J","year":"1996"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.9.noc50009"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21057"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200105000-00009"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-004-0238-z"},{"key":"e_1_2_6_21_2","article-title":"Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease","author":"Bandini F","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-006-2128-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20757"},{"key":"e_1_2_6_24_2","first-page":"441","article-title":"Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine","volume":"159","author":"Montastruc JL","year":"2003","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21098"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10625"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.02.004"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2006.04.017"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21072"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.2.298-a"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802e98c3"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21334"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.2.212"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNN.0b013e31802b6c34"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.102061"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000184487.72289.f0"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.141"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.2.299-b"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1378"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199905)45:5<601::AID-ANA8>3.0.CO;2-0"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2005.02.002"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0041-7"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0433-05.2005"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(00)00173-8"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20822"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.12.1386"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.06.005"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.65.5.727"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.152.2.284"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00241-9"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21611","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:32:26Z","timestamp":1760963546000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,19]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,9,15]]}},"alternative-id":["10.1002\/mds.21611"],"URL":"https:\/\/doi.org\/10.1002\/mds.21611","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,19]]}}}